| By Sinobiopharma |
| Friday, 09 October 2009 |
 |
Sinobiopharma, Inc. (OTC Bulletin
|
|
Board:
SNBP) ("Sinobiopharma") (the "Company") is pleased to announce that the Company received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material (Certificate #2009S01805) from the Chinese State Food and Drug Administration ("SFDA").
Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and |
|
|
as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
The Company is now awaiting GMP certification to manufacture Gabexate mesylate.
About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest |
|
growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.
Want to read more?
West Dedicates Injection Molding Plant In China
New Liquids Technology Available At Process Expo 2009 In Las Vegas
GE Announces First Phased Array Corrosion Inspection Solution |
|
|
